Core Viewpoint - LakeShore Biopharma Co., Ltd has announced a merger agreement with Oceanpine Skyline Inc., implying an equity value of approximately US$37 million for the company [1]. Merger Details - The merger will involve the cancellation of each ordinary share of LakeShore Biopharma in exchange for US$0.90 in cash per share [2]. - The merger consideration represents a premium of approximately 15.4% to the closing price of the shares on August 15, 2025, and a premium of approximately 16.6% to the average closing price during the last 15 trading days prior to that date [3]. - Certain shareholders, known as Rollover Shareholders, have agreed to cancel their shares for newly issued shares of Parent as part of a support agreement [4]. Funding and Approval - The merger will be funded through a combination of cash contributions from Oceanpine Capital Inc. and equity rollover by the Rollover Shareholders [5]. - The board of directors has unanimously approved the merger agreement and will recommend that shareholders vote in favor of it [6]. - The merger is expected to close in the first quarter of 2026, pending approval from at least two-thirds of the votes cast by shareholders [7]. Advisory and Documentation - Kroll, LLC is serving as the financial advisor to the Special Committee, while various law firms are providing legal counsel [8]. - The company will file a current report with the U.S. Securities and Exchange Commission (SEC) regarding the merger, including the merger agreement [10]. - A proxy statement will be prepared and mailed to shareholders, along with a Schedule 13E-3 Transaction Statement [11].

Accessibility StatementSkip Navigation BEIJING, Sept. 10, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB, "LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that the independent special committee (the "Special Committee") of the Company's board of directors (the "Board"), formed to evaluate and c ...